NOKOMIS, Fla.--(BUSINESS WIRE)--Joining forces with Nano3D Biosciences is the first step in Rainbow Coral Corp.’s (OTCBB:RBCC) plans to take biotechnology out of the laboratory and into the marketplace.
“It’s our goal to help create a new business model to widely distribute the Bio-Assembler system into the health and research marketplace,” said RBCC CEO Patrick Brown. “This is a revolutionary cell culturing system that will dramatically shorten the development pipeline for cellular research into cures for chronic illnesses and debilitating injuries.”
The Bio-Assembler is a proprietary system developed by Nano3D Biosciences, Inc. (n3D) in collaboration with the MD Anderson Cancer Center and Rice University in Houston. The Bio-Assembler enables scientists to grow and study cells in a three-dimensional environment more easily than ever before. Rainbow BioSciences, RBCC’s new biotech division, is forging ahead with due diligence to acquire or form a new joint venture with the cutting-edge biotech firm.
The global market for bioscience innovations is booming. Companies in the biotech sector alone pulled in $25 billion in capital last year, a 15-percent jump from the previous record in 2007.
“We feel the sky is the limit for our future initiatives because we’re helping to transition leading-edge research into practical, affordable treatments for people who need them,” Brown said.
For more information on Rainbow BioSciences, RBCC’s biotechnology division, please visit www.rainbowbiosciences.com/investors.
Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Cell Therapeutics, Inc. (NASDAQ: CTIC), Abbott Laboratories (NYSE: ABT) Affymax, Inc. (NASDAQ: AFFY), and Celgene Corp. (NASDAQ: CELG).
Follow us on Twitter at www.twitter.com/RBCCinfo.
About Rainbow BioSciences
Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.rainbowbiosciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.